Acceleron Pharma

Investors/Media

Press Releases

Date Title and Summary View
Toggle Summary Acceleron Announces Management Change
CAMBRIDGE, Mass. --(BUSINESS WIRE)-- Acceleron Pharma Inc. (NASDAQ: XLRN), a clinical stage biopharmaceutical company focused on the discovery, development and commercialization of innovative therapeutics to treat serious and rare diseases, today announced that Steven Ertel , due to medical
View HTML
Toggle Summary Acceleron to Participate in Two Healthcare Investor Conferences in May
CAMBRIDGE, Mass. --(BUSINESS WIRE)-- Acceleron Pharma Inc. (NASDAQ:XLRN), a clinical stage biopharmaceutical company focused on the discovery, development and commercialization of innovative therapeutics to treat serious and rare diseases, today announced that senior management will participate in
View HTML
Toggle Summary Acceleron Provides Clinical Development Updates on Luspatercept Program
- Enrollment in MEDALIST and BELIEVE Phase 3 studies now expected to be completed in Q2 2017 - - Acceleron and Celgene to initiate an additional Phase 3 trial in first-line, lower-risk MDS in early 2018 to expand opportunity beyond ongoing MEDALIST study - CAMBRIDGE, Mass.
View HTML
Toggle Summary Acceleron to Host Webcast to Review First Quarter 2017 Financial and Operational Results on May 8, 2017
- Management to review highlights from luspatercept clinical presentations at the 14 th International MDS Symposium - CAMBRIDGE, Mass. --(BUSINESS WIRE)-- Acceleron Pharma Inc. (NASDAQ:XLRN), a clinical stage biopharmaceutical company focused on the discovery, development and commercialization of
View HTML
Toggle Summary Acceleron Announces Clinical Presentations on Luspatercept at the 14th International Symposium on Myelodysplastic Syndromes
Oral presentation highlights new Phase 2 data in additional sub-populations of lower-risk MDS CAMBRIDGE, Mass. --(BUSINESS WIRE)-- Acceleron Pharma Inc. (NASDAQ:XLRN), a clinical stage biopharmaceutical company focused on the discovery, development and commercialization of innovative therapeutics
View HTML
Toggle Summary Acceleron Announces Plans to Initiate a Phase 2 Trial of ACE-083 in Charcot-Marie-Tooth Neuromuscular Disease and Host Educational Webinar
- Second Phase 2 study for ACE-083 expected to begin 2H 2017 - - Company to host educational webinar with leading clinical researcher on April 3 rd at 11:00 a.m. EDT - CAMBRIDGE, Mass. --(BUSINESS WIRE)-- Acceleron Pharma Inc. (NASDAQ:XLRN), a clinical stage biopharmaceutical company focused on the
View HTML
Toggle Summary Acceleron Reports Fourth Quarter and Year Ended 2016 Operational and Financial Results
- Luspatercept Phase 3 trials to complete enrollment in both the MDS ("MEDALIST") and beta-thalassemia ("BELIEVE") trials in 2H 2017 - - Presented data from five abstracts on luspatercept and sotatercept at the American Society of Hematology Annual Meeting in December - - Treated first patient in
View HTML
Toggle Summary Acceleron to Participate in Two Healthcare Investor Conferences in March
CAMBRIDGE, Mass. --(BUSINESS WIRE)-- Acceleron Pharma Inc. (NASDAQ:XLRN), a clinical stage biopharmaceutical company focused on the discovery, development and commercialization of innovative therapeutics to treat serious and rare diseases, today announced that senior management will participate in
View HTML
Toggle Summary Acceleron Pharma to Webcast Conference Call of Fourth Quarter and Year Ended 2016 Financial Results on March 1, 2017
CAMBRIDGE, Mass. --(BUSINESS WIRE)-- Acceleron Pharma Inc. (NASDAQ:XLRN), a clinical stage biopharmaceutical company focused on the discovery, development and commercialization of innovative therapeutics to treat serious and rare diseases, today announced that the Company will host a live
View HTML
Toggle Summary Acceleron to Participate in Two Healthcare Investor Conferences in February
CAMBRIDGE, Mass. --(BUSINESS WIRE)-- Acceleron Pharma Inc. (NASDAQ: XLRN), a clinical stage biopharmaceutical company focused on the discovery, development and commercialization of innovative therapeutics to treat serious and rare diseases, today announced that senior management will participate in
View HTML